Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jan 30;18(4):744–759. doi: 10.1074/mcp.RA118.000958

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Menneteau et al.

Published by The American Society for Biochemistry and Molecular Biology, Inc.

Author's Choice—Final version open access under the terms of the Creative Commons CC-BY license.

PMC Copyright notice

Fig. 5. — Expansion of ADSCs in different O₂ levels affect 20S proteasome status and ADSCs' capacity to differentiate. A, Proteasome 20S absolute quantity (% w/w total proteins) measured by the LC-SRM method in five patients derived primary ADSCs cultivated at three different levels of O₂ (1%, 5%, and 20%). B, Proteasome 20S chymotrypsin-like activity measured by the in vitro degradation of the LLVY-AMC peptide by proteasome in ADSCs lysates after cultivation in three different levels of O₂ (1%, 5%, and 20%) (n = 5 patients − 3 technical replicates). C, Relative content of standard and immuno catalytic 20S proteasome subunits measured by the method in five patients derived primary ADSCs cultivated at three different levels of O₂ (1%, 5%, and 20%). D, Differentiation potential of human ADSCs from different patients under different levels of O₂ (1%, 5%, and 20%). The immunoproteasome inhibitor ONX-0914 alters the differentiation capacity of ADSCs at 5 and 20% O₂ concentrations. Adipogenic differentiation is indicated by Oil red O staining.